31 Dec mcr-1 colistin resistance gene
Constance Schultsz et al. did a prospective study of acquisition of fecal colonisation and carriage with extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae in 2001 Dutch travellers (the COMBAT study),2from November, 2012, to November, 2013. Acquisition was defined as the absence of ESBL-producing Enterobacteriaceae in a fecal swab sample taken immediately before travel and detection of ESBL-producing Enterobacteriaceae in a sample taken within 1–2 weeks after return to the Netherlands. Of 1847 travellers at risk, 633 (34%) acquired ESBL-producing Enterobacteriaceae. Nine of these 633 travellers acquired ESBL-producing Escherichia coli with a colistin minimum inhibitory concentration of 4–8 mg/L (EUCAST clinical breakpoint for resistance >2 mg/L) as detected using Vitek-2 and confirmed by E-test.
Dissemination published in The Lancet